Strategic License Agreements (Details) - USD ($)		1 Months Ended	12 Months Ended
	Jul. 27, 2023	Jul. 31, 2021	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2023
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total revenue			$ 0	$ 0	$ 886,000
Proceeds from sale of in-process research & development asset			7,000,000	0	15,000,000
Gain on sale of in-process research and development asset			10,000,000	0	16,449,000
Total consideration from disposal of long lived assets						$ 500,000
Contract assets			0	0
Contract liability			0	0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights to Pegzilarginase
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from sale of in-process research & development asset	$ 15,000,000.0
Contingent consideration	100,000,000.0
Carrying value of assets	0
Gain on sale of in-process research and development asset	16,400,000		10,000,000.0
Contingent reimbursement of pre-paid manufacturing costs	1,800,000
Derecognition of nonfinancial assets and liabilities	$ 400,000
Total consideration from disposal of long lived assets			$ 3,000,000.0	$ 0
Immedica Pharma AB
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Reimbursement		$ 3,000,000.0
Immedica Pharma AB | PEACE Trial and BLA Package
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total revenue					$ 900,000